Bone Biologics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Bone Biologics prognostiziert ein Gewinnwachstum at 30.7% per annum. Der Gewinn pro Aktie wird voraussichtlich wachsen um 55% pro Jahr.

Wichtige Informationen

30.7%

Wachstumsrate der Gewinne

55.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Jun 07

Bone Biologics prices $5.1M underwritten public offering

Oct 07

We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Mar 18

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:BBLG - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-4	N/A	N/A	1
12/31/2025	N/A	-4	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
9/30/2024	N/A	-7	-5	-5	N/A
6/30/2024	N/A	-5	-7	-7	N/A
3/31/2024	N/A	-6	-10	-10	N/A
12/31/2023	N/A	-9	-10	-10	N/A
9/30/2023	N/A	-7	-9	-9	N/A
6/30/2023	N/A	-6	-7	-7	N/A
3/31/2023	N/A	-5	-4	-4	N/A
12/31/2022	N/A	-1	-4	-4	N/A
9/30/2022	N/A	-3	-2	-2	N/A
6/30/2022	N/A	-2	-2	-2	N/A
3/31/2022	N/A	-2	-2	-2	N/A
12/31/2021	N/A	-2	-1	-1	N/A
9/30/2021	N/A	-2	-1	-1	N/A
6/30/2021	N/A	-2	-1	-1	N/A
3/31/2021	N/A	-2	0	0	N/A
12/31/2020	N/A	-2	0	0	N/A
9/30/2020	N/A	-2	-1	-1	N/A
6/30/2020	N/A	-2	-1	-1	N/A
3/31/2020	N/A	-3	-2	-2	N/A
12/31/2019	N/A	-3	-3	-3	N/A
9/30/2019	N/A	-4	-4	-4	N/A
6/30/2019	N/A	-4	-5	-5	N/A
3/31/2019	N/A	-4	-4	-4	N/A
12/31/2018	N/A	-4	-4	-4	N/A
9/30/2018	N/A	-6	-4	-4	N/A
6/30/2018	N/A	-8	N/A	-3	N/A
3/31/2018	N/A	-6	N/A	-3	N/A
12/31/2017	N/A	-7	N/A	-3	N/A
9/30/2017	N/A	-14	N/A	-4	N/A
6/30/2017	N/A	-16	N/A	-5	N/A
3/31/2017	N/A	-22	N/A	-6	N/A
12/31/2016	N/A	-26	N/A	-7	N/A
9/30/2016	N/A	-24	N/A	-7	N/A
6/30/2016	N/A	-23	N/A	-7	N/A
3/31/2016	N/A	-19	N/A	-6	N/A
12/31/2015	N/A	-14	N/A	-4	N/A
9/30/2015	N/A	-7	N/A	-4	N/A
6/30/2015	N/A	-6	N/A	-4	N/A
3/31/2015	N/A	-6	N/A	-3	N/A
12/31/2014	N/A	-4	N/A	-3	N/A
9/30/2014	N/A	-4	N/A	-1	N/A
6/30/2014	N/A	-1	N/A	0	N/A
3/31/2014	N/A	-1	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BBLG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: BBLG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: BBLG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von BBLG schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: BBLG wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BBLG in 3 Jahren voraussichtlich hoch sein wird

Bone Biologics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to US$4.88

Price target decreased to US$4.88

Recent updates

New major risk - Financial position

Bone Biologics Corporation Appoints Phillip Meikle to Board of Directors

Bone Biologics Corporation Announces Resignation of Don Hankey as Director, Effective Immediately

Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $1.143121 million.

Bone Biologics Corporation, Annual General Meeting, Sep 17, 2024

New major risk - Share price stability

Bone Biologics Corporation Announces First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine Fusion

Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $1.99934 million.

Bone Biologics Corporation has completed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Bone Biologics Corporation has filed a Follow-on Equity Offering.

Bone Biologics Corporation Announces Board Changes

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $0.729 million.

Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million.

Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million.

Bone Biologics Corporation Receives Non-Compliance Notice From Nasdaq

New major risk - Financial position

Bone Biologics Corporation, Annual General Meeting, Sep 12, 2023

New major risk - Share price stability

Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Nasdaq Notifies Bone Biologics Regarding Non-Compliance with the Minimum Bid Price Requirement

Bone Biologics Corporation Resigns Stephen Laneve as Director

Bone Biologics Receives Written Notice from the NASDAQ Regarding Minimum Bid Price Requirement

Price target decreased to US$4.88

Price target decreased to US$4.88

Bone Biologics Corporation has completed a Composite Units Offering.

Bone Biologics Corporation has completed a Composite Units Offering in the amount of $5.1 million.

Bone Biologics prices $5.1M underwritten public offering

Bone Biologics Corporation, Annual General Meeting, Aug 23, 2022

We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Less than half of directors are independent

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken